Clinical Trials · NCT05096598
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Zealand Pharma
- Enrollment
- 64
- Start date
- Oct 2021
- Locations
- 1 site, Germany
- Primary endpoint
- Incidence of treatment emergent adverse events (TEAEs)